Gene patenting ruling unlikely to really impact oncology care

Gene patenting ruling unlikely to really impact oncology care
The Supreme Court decision in Association for Molecular Pathology v. Myriad is not likely to have much immediate impact the practice of oncology, according to a special communication published online June 13 in the Journal of Clinical Oncology.

(HealthDay)—The Supreme Court decision in Association for Molecular Pathology v. Myriad is not likely to have much immediate impact the practice of oncology, according to a special communication published online June 13 in the Journal of Clinical Oncology.

Kenneth Offit, M.D., M.P.H., from the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues reviewed previous court cases and , as well as earlier rulings in the course of this case.

The authors note that, for most common other than BRCA, which is at the center of this case, genetic testing is not restricted by exclusive patent enforcement. Isolated DNA patents are already becoming obsolete with the advent of next generation sequencing technologies. Additionally, methods patents based on DNA sequence have already been weakened by earlier rulings. Patents related to new drug development usually involve cellular methods and thus will not likely be impacted by this case.

"It is important that judicial and legislative actions in this area maximize genomic discovery while also ensuring patients' access to personalized cancer care," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

High court ruling on gene patents lifts Myriad

Jun 13, 2013

Shares of diagnostic test maker Myriad Genetics Inc. are jumping Thursday after the Supreme Court issued a mixed ruling in a case involving the company's patents on genes at the center of its tests for increased risk of bre ...

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

15 hours ago

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.